Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, leading to the rapid growth of abnormal white blood cells that interfere with normal blood cell production.
Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant
We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Myelodysplastic Neoplasia (MDS)
Myelodysplastic Neoplasia (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells, leading to ineffective blood cell production and a higher risk of developing leukemia.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Are you currently pregnant or breastfeeding?
- Do you have a history of significant heart problems, like heart failure or recent heart attack?
- Are you taking any medications that could affect your heart rhythm, like certain heart medications or antidepressants?
- Have you had a stem cell transplant in the past 100 days?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Klinikum Chemnitz gGmbH
Klinik für Innere Medizin III
Chemnitz, Germany
Technische Universitaet Dresden
Medizinische Klinik und Poliklinik I
Dresden, Germany
Universitaetsklinikum Essen AöR
Klinik für Hämatologie und Stammzelltransplantation
Essen, Germany
Sponsor: Technische Universitat Dresden
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.